Dr Michael Cardoso
/content/dam/asset-migration/headshots/au-doctor-headshots/AU_Oncology_Headshot_GA_Dr Michael Cardoso.jpg

Dr Michael Cardoso

Dr Michael Cardoso
Michael
Cardoso
BMedRadPhysAdv (Hons Class 1), MBBS, FRANZCR, Radiation Oncologist

Languages spoken

English, Portuguese

Overview

Clinical interest in Breast cancer, skin cancer, prostate cancer, bladder cancer, palliative care, stereotactic ablative body radiotherapy (SABR), stereotactic radiosurgery (SRS), and brain cancer.

Michael Cardoso is a radiation oncologist with sub-speciality interests in breast cancer, skin cancer, prostate cancer, bladder cancer, brain cancer, stereotactic radiotherapy, and palliative care.

Graduating with first class honours from the University of Wollongong with a Bachelor of Medical and Radiation Physics Advanced followed by a Bachelor of Medicine and Bachelor of Surgery, he undertook specialist radiation oncology training at Liverpool, Campbelltown and Wollongong Hospitals. Michael subsequently did a clinical radiation oncology fellowship in genitourinary cancers, head and neck cancers, and stereotactic radiotherapy.

Thriving off a mixture of teaching, research, and clinical work, he is a conjoint lecturer at the Western Sydney University and University of New South Wales and has published in multiple peer reviewed journals. Michael is an active member of several leading cancer clinical trial groups. Michael is passionate about providing evidence-based and personalised care to his patients while working within a multidisciplinary team.

Research interests

Research interests include: MRI in radiation therapy, developing technological advances, target volume delineation quality assurance, adaptive radiotherapy, and understanding predictors for radiation toxicity.

Professional memberships

  • The Royal Australian and New Zealand College of Radiologists (RANZCR)
  • The Faculty of Radiation Oncology Genito-urinary Group (FROGG)
  • The Cooperative Trials Group for Neuro-Oncology (COGNO)
  • The Trans-Tasman Radiation Oncology Group (TROG)
  • The Australian and New Zealand Palliative Radiation Oncology Group (APROSIG)

Publications

  • Cardoso M, Sidhom M, Udovitch M, Young T, Arumugam S. Implementing online position monitoring for prostate radiotherapy using an in-house position monitoring system: User experience and impact on workforce. J Med Imaging Radiat Oncol. 2023 Feb;67(1):111-118. doi: 10.1111/1754-9485.13499. Epub 2022 Dec 20. PMID: 36537583.
  • Min H, Dowling J, Jameson MG, Cloak K, Faustino J, Sidhom M, Martin J, Cardoso M, Ebert MA, Haworth A, Chlap P, de Leon J, Berry M, Pryor D, Greer P, Vinod SK, Holloway L. Clinical target volume delineation quality assurance for MRI-guided prostate radiotherapy using deep learning with uncertainty estimation. Radiother Oncol. 2023 Sep;186:109794. doi: 10.1016/j.radonc.2023.109794. Epub 2023 Jul 4. PMID: 37414257.
  • Cardoso M, Ngo D, Lim K, Wong K, Sidhom M. Interim Prostate-Specific Antigen: Predicting for Biochemical Failure During Salvage Radiation Therapy After Prostatectomy. Adv Radiat Oncol. 2021 Jan 16;6(2):100646. doi: 10.1016/j.adro.2021.100646. PMID: 33912736; PMCID: PMC8071726.
  • Cardoso M, Choudhury A, Christie D, Eade T, Foroudi F, Hayden A, Holt T, Kneebone A, Sasso G, Shakespeare TP, Sidhom M. FROGG patterns of practice survey and consensus recommendations on radiation therapy for MIBC. J Med Imaging Radiat Oncol. 2020 Dec;64(6):882-893. doi: 10.1111/1754-9485.13120. Epub 2020 Oct 28. PMID: 33118330.
  • Cardoso M, Min M, Jameson M, Tang S, Rumley C, Fowler A, Estall V, Pogson E, Holloway L, Forstner D. Evaluating diffusion-weighted magnetic resonance imaging for target volume delineation in head and neck radiotherapy. J Med Imaging Radiat Oncol. 2019 Jun;63(3):399-407. doi: 10.1111/1754-9485.12866. Epub 2019 Feb 28. PMID: 30816646.